Myrbetriq Generic 2026: Mirabegron Cost & How to Save
Generic mirabegron has been FDA-approved since September 2022. So why does your pharmacy still quote you $400 for thirty tablets?
That gap — between "a generic exists" and "the generic is affordable" — is where most people looking up the Myrbetriq generic get stuck. The short version: approval and actual availability are two different things, and even now, four years on, competition in the mirabegron market is thinner than the approval list suggests.
At a glance
- The generic for Myrbetriq is mirabegron extended-release, available in 25 mg and 50 mg tablets
- Lupin and Zydus won FDA approval in September 2022 but didn't actually put product on US shelves until January–September 2024
- Cash prices for 30 generic tablets ranged from roughly $189 to $681 in the first half of 2026 depending on where you filled — the generic is sometimes quoted higher than the brand
- Six manufacturers now hold approvals, with Amneal launching in April 2026, which should keep pushing prices down
- Cash-pay routes, including CanAmerica Plus at $129.99 for 100 tablets, can cut the per-tablet cost dramatically
Is there a generic for Myrbetriq?
Yes. The generic name is mirabegron, sold as mirabegron extended-release tablets in 25 mg and 50 mg strengths. It's the same active ingredient, same dose, same once-daily extended-release delivery, and the FDA has rated the approved versions as therapeutically equivalent to brand Myrbetriq.
Astellas got brand Myrbetriq approved on June 28, 2012. The first generic approvals came a decade later.
There's also a pediatric formulation — mirabegron extended-release oral suspension, 8 mg/mL — used for neurogenic detrusor overactivity in children. Several sources still say that one is brand-only. That's out of date, and we'll come back to it.
When did generic mirabegron actually become available?
This is the part most pages get wrong, so here's the full record.
| Manufacturer | FDA approval | First US marketing |
|---|---|---|
| Lupin | Sept 28, 2022 | 25 mg: Apr 19, 2024 · 50 mg: Sept 3, 2024 |
| Zydus | Sept 29, 2022 | Jan 23, 2024 |
| Alkem Labs | Feb 12, 2024 | — |
| Qilu | June 30, 2025 | June 30, 2025 |
| MSN | Nov 4, 2025 | — |
| Amneal | — | Apr 19, 2026 |
| Deva Holding | May 1, 2026 | — |
Look at the first two rows. Lupin and Zydus were approved within a day of each other in September 2022, and neither product reached pharmacies for roughly sixteen months. Zydus went first in January 2024. Lupin's 25 mg followed that April; the 50 mg — the strength most adults end up on — didn't launch until September 2024.
So if you read somewhere that generic Myrbetriq "became available in late 2022," that's an approval date being mistaken for a launch date. Real-world availability of the 50 mg started in the fall of 2024.
Why the delay? Patent litigation settlements routinely set a launch date years after approval — the same pattern that held up generic Xarelto and generic Entresto. Astellas holds a stack of formulation patents on the extended-release system that run to September 2029, with pediatric extensions into March 2030. Generic makers can be approved and still be contractually barred from selling until an agreed date.
How much does generic mirabegron cost in 2026?
Prices for the exact same thing — 30 extended-release tablets, 50 mg — were all over the map through the first half of 2026:
| Source | Price for 30 × 50 mg | Date context |
|---|---|---|
| Average US retail (GoodRx) | $452.88 | 2026 |
| Discount-card price (GoodRx) | from $121.10 | 2026 |
| Average cash price, generic (SingleCare, ZIP 23666) | $681 | Mar 24, 2026 |
| Average cash price, brand (SingleCare, ZIP 23666) | $625 | Mar 24, 2026 |
| Discount-card price, generic (SingleCare) | $189 at CVS | Mar 24, 2026 |
| Drugs.com price guide, generic | from $355.78 | Mid-2026 |
| CanAmerica Plus, brand Myrbetriq | $129.99 per 100 tablets (~$39 per 30) | July 2026 |
Yes, one of those rows says the generic averaged $681 while the brand averaged $625. That's not a typo, and it's not unusual for a generic that launched into a market with limited competition.
If those numbers feel irreconcilable, it's because they're measuring different things:
- Average retail / cash price — what a pharmacy charges someone walking in with no card and no coverage. This is the highest number and the one most people actually get quoted.
- Discount-card price — a negotiated rate a card processor has arranged with that specific chain. Varies by chain, by ZIP code, and week to week.
- Insured copay — whatever your plan's tier assigns. Could be $10, could be $150, could be a rejection until you clear prior authorization.
- Cash-pay network price — a flat price for the medication itself, outside the insurance system entirely.
Same tablet. Five different answers.
Savings tip: 25 mg and 50 mg mirabegron cost close to the same per tablet at most pharmacies — GoodRx listed them at $120.60 and $121.10 for 30. If your prescriber starts you at 25 mg with a plan to move up, you're paying nearly full freight for the lower dose. Ask whether it makes sense to fill a longer supply once you're settled on a dose rather than two short fills during titration.
Why isn't generic mirabegron cheaper?
The usual rule is that generics land 80–85% below the brand once several manufacturers are competing. Mirabegron hasn't followed that curve, for three reasons.
Not enough sellers, for a long time. From January 2024 through mid-2025, essentially two companies supplied the US market. Two suppliers is a duopoly, not competition. Price erosion in generics tracks the number of active sellers, and it usually takes four or more before cash prices really collapse.
The formulation is hard to copy. Myrbetriq isn't a simple immediate-release tablet. It uses a controlled-absorption extended-release system, and the Astellas patents that run to 2029 are specifically about that delivery mechanism. Building a bioequivalent ER tablet that clears FDA review is expensive, which keeps the number of entrants down.
Big brand, big incentive to defend it. Mirabegron ER tablets were a roughly $2.4 billion-a-year US market as of early 2024. That's worth litigating over.
The direction is finally right, though. Qilu launched in mid-2025, MSN was approved in late 2025, and Amneal began marketing in April 2026. That's four to six sellers instead of two, and cash prices should keep sliding through 2026 and 2027.
Brand Myrbetriq vs generic mirabegron: what's actually different?
Clinically, not much. To win approval, a generic has to contain the same active ingredient at the same strength, in the same dosage form, taken the same way, and demonstrate bioequivalence — meaning it delivers the drug into your bloodstream at a comparable rate and extent.
What can differ: the inactive ingredients. Fillers, binders, coatings, and dyes vary between manufacturers. For most people this is irrelevant. For a small number with a dye sensitivity or a particular intolerance, it isn't, and that's a real conversation to have with your pharmacist rather than something to dismiss.
The tablets also look different depending on who made them:
| Manufacturer | Strength | Imprint | Appearance |
|---|---|---|---|
| Lupin | 25 mg | LU M25 | White, oval |
| Lupin | 50 mg | LU M50 | Yellow, oval |
| Zydus | 50 mg | 1160 | Yellow, oval |
If your refill looks different from last month's, it usually means your pharmacy switched wholesalers or manufacturers — not that you got the wrong drug. Check the imprint against the label before you worry.
What about the pediatric oral suspension?
Several widely-read drug pages still say the granules-for-suspension formulation is brand-name only. As of 2026 that's no longer true.
Alkem Labs received FDA approval for generic mirabegron extended-release oral suspension, 8 mg/mL, on January 20, 2026, and Ascend Laboratories began marketing a generic suspension on June 15, 2026. Availability at any given pharmacy is another matter — a newly launched pediatric suspension often has to be specially ordered.
Worth noting separately: Astellas holds a patent on the pediatric ER suspension running to March 2036, so prices for this formulation may stay high far longer than they do for the tablets.
How does mirabegron compare with other overactive bladder medications?
Mirabegron is a beta-3 adrenergic agonist. It relaxes the bladder muscle during filling so the bladder holds more before signaling urgency. That mechanism is different from the older anticholinergics, which is why it's often chosen for people who can't tolerate dry mouth, constipation, or the cognitive fog anticholinergics can cause in older adults.
Here's how the class stacks up on cost, using CanAmerica Plus pricing as of July 2026:
| Medication | Class | Generic available? | CanAmerica Plus price |
|---|---|---|---|
| Myrbetriq (mirabegron) | Beta-3 agonist | Yes, since 2024 | $129.99 / 100 tablets |
| Gemtesa (vibegron) | Beta-3 agonist | No | $129.99 / 30 tablets |
| Vesicare / solifenacin | Anticholinergic | Yes | $73.99 / 100 tablets |
| Toviaz (fesoterodine) | Anticholinergic | Yes | $99.99 / 30 tablets |
| Detrol LA / tolterodine | Anticholinergic | Yes | Varies by strength |
Two things stand out. Gemtesa, the other beta-3 agonist, has no generic at all — so if you're choosing between the two on price, mirabegron has a structural advantage. (We broke down what Gemtesa costs in 2026 separately.) And solifenacin, a fully mature generic with many manufacturers, is the cheapest option in the group, which is exactly what mirabegron pricing should eventually look like once enough sellers are in.
Oxybutynin is cheaper still — often under $15 for a month at US retail — but it's also the anticholinergic with the heaviest side-effect burden, particularly in older adults. Cheapest isn't automatically best here. That's a decision for you and your prescriber.
Side effects: same drug, same profile
Generic mirabegron carries the identical safety profile as brand Myrbetriq, because it's the same molecule.
The most common issues reported in adult trials:
- Increased blood pressure — 8% to 11%
- Cold-like symptoms (nasopharyngitis) — about 4%
- Urinary tract infection — 3% to 4%
- Headache — 2% to 3%
- Constipation — about 2%
Blood pressure is the one that deserves attention. Mirabegron can raise it, and it isn't recommended if yours is uncontrolled. Get a reading before you start and check it periodically after.
Less common but serious: angioedema (swelling of the face, lips, or throat — stop the drug and get medical help), and urinary retention, particularly if you have bladder outlet obstruction or you're also taking an anticholinergic.
Dosing runs lower in certain situations. With severe kidney impairment or moderate liver impairment, 25 mg once daily is the ceiling. It isn't recommended with end-stage renal disease or severe liver impairment at all. Swallow the tablets whole — crushing or chewing breaks the extended-release mechanism.
Mirabegron also inhibits CYP2D6, so it can raise levels of drugs like metoprolol, desipramine, flecainide, propafenone, and thioridazine, and it interacts with digoxin and warfarin. Give your prescriber the full list of what you take.
How to pay less for mirabegron
Ask what the cash price is, without running it through insurance. For a generic in a copay tier above roughly $50, the cash price is sometimes lower. Pharmacies won't usually volunteer this — you have to ask.
Price more than one pharmacy. The 2026 data showed the same 30 tablets at $115 with one program at Walgreens and $408 at Costco. Spread like that between chains in the same town is common with generics that haven't matured.
Fill 90 days instead of 30 once you're stable on a dose. Per-tablet cost usually drops, and you cut two dispensing fees.
Ask the pharmacy to order the generic if they only stock brand. Some pharmacies default to what's on the shelf. A generic is substitutable in most states unless your prescriber wrote "dispense as written."
Look at cash-pay networks. CanAmerica Plus lists brand Myrbetriq at $129.99 for 100 tablets in either 25 mg or 50 mg — roughly $1.30 a tablet, or about $39 for a 30-day supply. Set against the $355–$681 range for 30 tablets at US retail in early 2026, that's a substantial difference, and it's the brand product rather than a generic substitute.
Savings tip: If you're insured and your plan requires prior authorization or step therapy for mirabegron, ask your prescriber's office to submit the documentation showing which anticholinergics you've already tried and why they didn't work or weren't tolerated. That's usually what the plan is waiting on. Meanwhile, pricing a cash option keeps you from going without while the paperwork moves.
The bottom line
The Myrbetriq generic exists and has since 2022 on paper, since 2024 in practice — but it hasn't yet delivered the 80% discount people expect from a generic, because too few manufacturers have been selling it. With Qilu, MSN, Amneal, and Deva now in or entering the market, that's changing.
Until it does, the price you're quoted depends almost entirely on where you fill and how you pay. Compare the cash price against your copay, check more than one pharmacy, and price a cash-pay option before you assume there's nothing to be done. If mirabegron isn't working for you at any price, ask your prescriber about solifenacin, which is both fully generic and inexpensive.
Frequently asked questions
Is generic mirabegron as effective as Myrbetriq?
Yes. FDA-approved generics must contain the same active ingredient at the same strength and demonstrate bioequivalence to the brand. The approved mirabegron ER tablets carry an AB therapeutic-equivalence rating, meaning they're considered substitutable for Myrbetriq. Inactive ingredients can differ between manufacturers, which occasionally matters for someone with a specific sensitivity.
Why is generic mirabegron still so expensive?
Limited competition and a complicated formulation. From early 2024 to mid-2025, only two companies supplied the US market, and generic prices don't fall much until four or more sellers are competing. Astellas patents on the extended-release delivery system also run into 2029, which raised the barrier to entry. Additional manufacturers launching in 2025 and 2026 should keep pushing prices down.
Can I ask my pharmacy for a specific manufacturer's mirabegron?
You can ask, though pharmacies stock what their wholesaler supplies and may not be able to accommodate it. If a particular version genuinely didn't agree with you, tell your pharmacist — they can note it and try to source a different one. Check the imprint on your tablets (LU M25, LU M50, and 1160 are among the common ones) so you can identify what you've been getting.
Is there a generic for Gemtesa too?
Not as of July 2026. Gemtesa (vibegron) is the other beta-3 agonist for overactive bladder and has no approved generic yet, which makes mirabegron the only medication in that class with a generic option.
Does mirabegron cost the same at 25 mg and 50 mg?
Essentially, yes. Discount-card pricing in 2026 listed 30 tablets at $120.60 for 25 mg and $121.10 for 50 mg, and the Drugs.com price guide showed both strengths starting from the same figure. Per-tablet pricing that ignores strength is common with extended-release generics.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment. Pricing information is current as of the publication date but may change. Verify pricing directly before making purchasing decisions.
